Epitalon (AEDG) Dosage Protocol Guide — Reconstitution, Research Cycles & Telomerase Research (2026)

# Epitalon (AEDG) Dosage Protocol Guide — Reconstitution, Research Cycles & Telomerase Research (2026)

> Research Use Only Disclaimer: Epitalon is a research compound. All dosing information, protocols, and data referenced in this article are derived from preclinical and clinical research literature. This content is intended for educational and scientific reference purposes only. Epitalon is not approved by the FDA for therapeutic use in humans. It is not a dietary supplement and should not be used for self-treatment or human consumption.

Epitalon — the synthetic tetrapeptide Ala-Glu-Asp-Gly (AEDG) — has attracted sustained scientific interest for its reported ability to activate telomerase, extend telomere length, and modulate pineal gland function. First isolated from bovine pineal extract by Russian biogerontologist Vladimir Khavinson in the 1980s, Epitalon has been studied in over three decades of institutional research — predominantly from the St. Petersburg Institute of Bioregulation and Gerontology — with findings spanning in vitro telomerase activation, animal longevity studies, and limited human clinical trials.

This guide compiles the dosing parameters, reconstitution protocols, administration approaches, and cyclical regimen structures reported across that body of literature. All information is presented for scientific reference only, in the context of preclinical and human research.

---

What Is Epitalon? Tetrapeptide Structure and Pineal Origin

Epitalon is a synthetic tetrapeptide consisting of four amino acids: Alanine–Glutamic acid–Aspartic acid–Glycine (AEDG). It was synthesized by Khavinson's team as a short-chain bioregulatory peptide derived from Epithalamin, a natural polypeptide complex extracted from bovine pineal gland tissue.

The pineal gland plays a central role in circadian regulation through melatonin synthesis. Khavinson's foundational hypothesis was that bioregulatory peptides secreted by the pineal gland could exert gene-regulatory effects on aging tissues by interacting with histone proteins and modifying chromatin accessibility — a concept central to his "peptidomimetic" model of bioregulation.

Key structural properties of Epitalon:

• •Molecular weight: ~390 Da
• •Sequence: H-Ala-Glu-Asp-Gly-OH
• •Solubility: Readily soluble in water and acetic acid solutions
• •Stability: Lyophilized form stable for extended periods under appropriate storage conditions

Epitalon's primary mechanism of research interest is telomerase activation. Published studies report that the peptide induces expression of the telomerase catalytic subunit (TERT) in somatic cell lines, extends telomere length in human fetal fibroblasts in vitro, and correlates with increased longevity in rodent models.

For a comprehensive review of Epitalon's mechanism of action, receptor interactions, and preclinical findings, see the companion article: Epitalon (AEDG Peptide): The Pineal Tetrapeptide in Telomerase and Aging Research.

---

Research Dosing: What the Literature Reports

The dose ranges in published Epitalon research vary by administration route, species, and endpoint. The human clinical trial literature — predominantly from Khavinson and colleagues — provides the most commonly cited reference dosages.

Human Clinical Trial Dosages

The primary human studies from the St. Petersburg Institute used the following dosage parameters:

The most commonly cited dosing range in human research is 5–10 mg per injection, administered daily for 10–20 consecutive days, with cycle repetition at 4–6 month intervals in longer observational studies.

Animal Model Dosages

In rodent longevity studies, doses are typically scaled differently than human research:

• •Mice (Anisimov et al.): 0.1–1 mg/kg body weight, administered subcutaneously
• •Drosophila and nematode models: Various concentrations reported in media supplementation
• •Rat models: 0.1–0.5 mg/animal/day in short cycles

Animal data provides mechanistic insight but should not be used to directly extrapolate human research dosages due to significant pharmacokinetic differences.

---

Reconstitution Protocol

Epitalon is typically supplied as a lyophilized (freeze-dried) powder in research vials of 5 mg or 10 mg. Reconstitution requires bacteriostatic water (BAC water) or sterile water for injection.

Standard Reconstitution Reference (10 mg vial)

Reconstitution procedure used in research settings:

1. Allow the vial to reach room temperature before opening

2. Use a sterile syringe to inject bacteriostatic water slowly down the vial wall — do not inject directly onto the lyophilized cake

3. Swirl gently; do not vortex or shake vigorously

4. Allow 5–10 minutes for complete dissolution; the solution should be clear and colorless

5. Inspect for particulate matter before use

For assistance with reconstitution volume calculations, see: Peptide Reconstitution Calculator

Reconstitution Notes from Research Literature

Research protocols typically use bacteriostatic water (0.9% benzyl alcohol in sterile water) because it extends the usable life of reconstituted peptide vials for multi-dose use. Plain sterile water for injection can be used for single-dose applications.

Epitalon in solution is reported to be stable for approximately 2–4 weeks at refrigerator temperatures (2–8°C). Some research labs use acetic acid (0.1–1%) in the reconstitution vehicle for improved solubility in certain formulations, though BAC water is generally sufficient.

---

Administration Routes in Research

Khavinson's published clinical studies used primarily subcutaneous (SQ) and intramuscular (IM) injection. More recent research community protocols have explored intranasal and oral routes, with important caveats about bioavailability.

Subcutaneous Injection (Primary Route in Literature)

The majority of human Epitalon research used subcutaneous injection, typically into the abdominal fat layer or the lateral thigh. This route provides:

• •Direct systemic absorption, bypassing first-pass hepatic metabolism
• •Consistent pharmacokinetic profile across study subjects
• •Ease of administration in outpatient and self-administration research contexts

Research injection volumes at 5 mg/mL concentration: 1 mL per 5 mg dose

Intramuscular Injection

Some Khavinson protocols used intramuscular injection, particularly for institutional clinical settings. The pharmacokinetic differences between SQ and IM routes for this small peptide are likely modest, though direct comparative data in published literature is limited.

Intranasal Administration — Research Notes

Intranasal Epitalon has been explored in some research contexts based on the hypothesis that bypassing the blood-brain barrier could allow more direct access to pineal tissue. However:

• •Bioavailability data for intranasal Epitalon is limited in the peer-reviewed literature
• •Nasal mucosa peptide absorption is highly sequence- and formulation-dependent
• •No controlled human studies have directly compared intranasal vs. subcutaneous Epitalon in terms of telomerase or hormonal endpoints

Some investigators reference intranasal protocols in the range of 1–2 mg per nostril, but this is not supported by the same level of clinical evidence as the SQ injection protocols.

Oral Administration — Stability Limitations

Oral Epitalon research is extremely limited. As a tetrapeptide, Epitalon is susceptible to gastrointestinal proteolytic degradation. Published research has not established oral bioavailability data for this compound. The primary Khavinson human studies exclusively used injectable routes.

---

Research Cycle Structures

Perhaps more distinctive than its per-dose amount is the cyclical protocol structure characteristic of Khavinson's research with Epitalon and related bioregulatory peptides.

The Standard Khavinson Research Cycle

The most cited research cycle structure from published human trials:

Cycle Pattern A — 10-Day Course (Most Common in Literature)

• •Duration: 10 consecutive days
• •Daily dose: 5–10 mg, subcutaneous
• •Frequency of repetition: Every 4–6 months (2 cycles/year) in longer observational studies
• •Example: Khavinson et al. used this structure in elderly subject studies measuring melatonin, cortisol, and immune biomarkers

Cycle Pattern B — 20-Day Extended Course

• •Duration: 20 consecutive days
• •Daily dose: 5 mg, subcutaneous
• •Used in some studies examining circadian hormone restoration and immune function in aged subjects
• •Repetition: Annually or semi-annually in published cohort data

Cycle Pattern C — Split Course Protocol

• •Reported in some research as: 10 days on, 20 days off, 10 days on
• •Total: 20 days of dosing within a 40-day window
• •Rationale cited: Avoidance of receptor saturation or desensitization, though direct mechanistic data on this point is limited in published literature

Research Cycle Summary Table

---

Circadian and Melatonin-Related Research Findings

A notable finding across multiple Khavinson studies is Epitalon's apparent influence on melatonin synthesis and circadian regulation in aged subjects.

Published findings from human studies in elderly cohorts reported:

• •Normalization of nocturnal melatonin secretion in subjects with age-related melatonin decline
• •Restoration of circadian cortisol rhythm patterns
• •Improved sleep quality metrics in some cohorts, including reduced sleep onset latency

This circadian dimension — derived from Epitalon's pineal gland origin — distinguishes it from most other research peptides. The proposed mechanism involves Epitalon's influence on pineal gland gene expression, modulating AANAT (arylalkylamine N-acetyltransferase) activity, a rate-limiting enzyme in melatonin synthesis.

From a research protocol perspective, some investigators administer Epitalon in the evening to align with the natural circadian window for melatonin synthesis, though the clinical literature does not uniformly specify injection timing. The 10-day course protocols in Khavinson's studies did not consistently specify morning vs. evening administration in the methods sections reviewed.

---

Epitalon vs. Other Khavinson Bioregulatory Peptides

Epitalon sits within a family of short-chain tissue-specific peptides developed by Khavinson's research program. Understanding how it compares to related compounds clarifies its specific research niche:

Epitalon shares its pineal origin with Endoluten and Pinealon, but is uniquely distinguished by telomerase activation data — a mechanism not prominently reported for the other pineal bioregulators. Its tetrapeptide length (vs. Endoluten's polypeptide complexity or Pinealon's tripeptide) also affects its bioavailability profile.

For a comprehensive overview of the full Khavinson peptide family, see: Khavinson Bioregulatory Peptides: Complete Guide

---

Storage and Stability

Proper storage is critical to maintaining peptide integrity across the research cycle.

Lyophilized (Dry) Powder Storage

• •Temperature: –20°C (standard laboratory freezer) for long-term storage; 2–8°C (refrigerator) for shorter-term storage
• •Light: Protect from light; store in opaque or amber vials when possible
• •Shelf life: Lyophilized Epitalon is generally reported as stable for 24–36 months at –20°C; shorter at refrigerator temperatures
• •Moisture: Keep vials sealed and desiccated until reconstitution

Reconstituted Solution Storage

• •Temperature: 2–8°C (refrigerator)
• •Duration: Approximately 2–4 weeks when reconstituted with bacteriostatic water; use within 24–48 hours if sterile water (no preservative) was used
• •Light: Protect from direct light; use amber-tinted or foil-wrapped vials when available
• •Freeze-thaw: Avoid repeated freeze-thaw cycles of reconstituted solution; this can degrade peptide structure

Transport

For short-distance transport, reconstituted Epitalon in a properly sealed vial can tolerate brief ambient temperature exposure (30–60 minutes) without significant degradation based on general peptide stability data, though minimizing temperature excursions is preferred.

---

Key Research Findings Summary

For context on how the research community interprets the Epitalon dosing literature:

Telomerase activation: Multiple in vitro studies (Khavinson et al., 2003; Kossoy et al., 2009) report dose-dependent increases in telomerase activity in human somatic cells following Epitalon exposure.

Telomere length: A landmark study by Khavinson and colleagues demonstrated statistically significant telomere elongation in human fetal fibroblasts treated with Epitalon in culture, representing one of the few published instances of a synthetic peptide extending telomere length in human cell lines.

Longevity in animal models: Multiple Anisimov et al. studies in mice reported increased mean and maximum lifespan in Epitalon-treated cohorts vs. controls, with effects noted on tumor latency and incidence.

Human biomarker data: Short-cycle human studies in elderly subjects reported improvements in melatonin secretion, cortisol rhythm, and various immune parameters (natural killer cell activity, T-cell subsets) following Epitalon administration.

Safety profile in literature: Across published human studies, Epitalon was reported as well-tolerated at the studied doses, with no serious adverse events attributed to the compound in the cited trials. Injection-site reactions were occasionally noted but not dose-limiting.

---

Important Research Caveats

The majority of published Epitalon human research originates from a single institutional group (St. Petersburg Institute of Bioregulation and Gerontology) led by or affiliated with Khavinson. While the volume of published work is substantial, independent replication in Western clinical settings is limited.

Key limitations of the existing literature:

• •Many studies lack full placebo-controlled, double-blind design
• •Sample sizes in human trials are generally modest (20–100 subjects)
• •The regulatory context differs substantially from FDA-approved therapeutic development
• •Long-term human safety data beyond the study periods is not available in published form

These limitations do not invalidate the existing data but contextualize how the findings should be interpreted within research applications.

---

Conclusion

Epitalon (AEDG) occupies a unique position in the Khavinson bioregulatory peptide family as the compound with the most direct and published evidence for telomerase activation and telomere effects. The research dosing literature consistently converges on 5–10 mg per day via subcutaneous injection, administered in 10–20 day course cycles repeated at 4–6 month intervals.

Reconstitution in bacteriostatic water at 5 mg/mL provides a convenient working concentration for research use. Proper cold-chain storage from lyophilized powder through reconstituted solution is essential for maintaining peptide integrity.

As with all Khavinson bioregulatory peptides, the research body for Epitalon is heavily concentrated in one institutional context and warrants independent replication. Nonetheless, the compound represents one of the more robustly studied short-chain synthetic peptides in the longevity/aging research space.

See also:

• •Epitalon Research Profile — Mechanisms, Telomerase & Aging Research
• •Khavinson Bioregulatory Peptides: Complete Guide
• •Peptide Reconstitution Calculator

---

This article is for educational and research reference purposes only. Epitalon is not approved by the FDA for any therapeutic use. This content does not constitute medical advice, and should not be used to guide any clinical or personal health decisions. For research use only.